Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.42 |
| ▸ | RAB9A | P51151 | 8/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 9/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.40 |
| ▸ | NPC1 | O15118 | 7/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5996784 | 1.00 | ALDH1A1 (0.42) | ALDH1A1RAB9AKDM4EHPGDTRPA1 | |
| SCHEMBL5996665 | 1.00 | ALDH1A1 (0.42) | ALDH1A1RAB9AKDM4EHPGDTRPA1 | |
| SCHEMBL5998749 | 0.89 | PIN1 (0.43) | ALDH1A1RAB9AKDM4EHPGDTRPA1 | |
| SCHEMBL5997869 | 0.89 | PIN1 (0.43) | ALDH1A1RAB9AKDM4EHPGDTRPA1 | |
| SCHEMBL5997875 | 0.89 | PIN1 (0.43) | ALDH1A1RAB9AKDM4EHPGDTRPA1 | |
| SCHEMBL5998520 | 0.86 | NPC1 (0.47) | ALDH1A1RAB9AMEN1KMT2ANPC1 | |
| SCHEMBL5996032 | 0.86 | NPC1 (0.47) | ALDH1A1RAB9AMEN1KMT2ANPC1 | |
| SCHEMBL5996035 | 0.86 | NPC1 (0.47) | ALDH1A1RAB9AMEN1KMT2ANPC1 | |
| SCHEMBL7266878 | 0.84 | ALDH1A1 (0.50) | ALDH1A1RAB9AKMT2ANPC1MAPK1 | |
| SCHEMBL29740352 | 0.84 | ALDH1A1 (0.50) | ALDH1A1RAB9AKMT2ANPC1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7094908-B2 | Reduction of carbonyl compounds using the carbonyl reductase of Kluyveromyces marxianus | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2006-08-22 | — | — | US | claimed |
| US-20030139464-A1 | Reduction of carbonyl compounds using the carbonyl reductase of kluyveromyces marxianus | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY | 2003-07-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139464-A1 | Reduction of carbonyl compounds using the carbonyl reductase of kluyveromyces marxianus | CBR1, CBR3, DCXR | ALDH1A1 216/4885RAB9A 3228/4885KDM4E 279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.